Table 2B. Bivariate analysis—Influence of DRD2 genotype on binding potential.

DRD2 genotype	CSF corrected SRTM2 raclopride: TBI			CSF corrected SRTM2 raclopride: control
	A1-carriers (N=7)	A2/A2 (N=5)		A1-carriers (N=6)	A2/A2 (N=7)
	Mean BP±s.e.m.	Mean BP±s.e.m.	P-value	Mean BP±s.e.m.	Mean BP±s.e.m.	P-value
Caudate	2.867±0.167	2.634±0.162	0.357	2.557±0.104	2.686±0.102	0.398
Putamen	2.874±0.147	2.696±0.096	0.379	2.861±0.104	2.943±0.106	0.595
Striatum	2.859±0.121	2.622±0.101	0.187	2.591±0.162	2.410±0.147	0.424

DAT genotype	9-carriers (N=6)	10/10 (N=6)		9-carriers (N=5)	10/10 (N=8)
	Mean BP±s.e.m.	Mean BP±s.e.m.	P-value	Mean BP±s.e.m.	Mean BP±s.e.m.	P-value
Caudate	2.662±0.147	2.918±0.147	0.228	2.708±0.108	2.576±0.097	0.394
Putamen	2.713±0.089	2.886±0.089	0.392a	3.013±0.154	2.838±0.066	0.254
Striatum	2.595±0.087	2.925±0.087	0.052	2.426±0.232	2.536±0.111	0.641

BP, binding potential; CSF, cerebrospinal fluid; DAT, dopamine transporter; DRD2, D2 receptor gene; TBI, traumatic brain injury.

^aEqual variance not assumed.